Back to top
more

Intersect ENT, Inc. (XENT)

(Delayed Data from NSDQ)

$33.65 USD

33.65
406,200

+1.22 (3.76%)

Updated May 3, 2019 04:00 PM ET

After-Market: $33.66 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sientra (SIEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.

    DexCom (DXCM) Misses Q1 Earnings Estimates

    by Zacks Equity Research

    DexCom (DXCM) delivered earnings and revenue surprises of -36% and 1.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    SeaSpine Holdings (SPNE) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.24% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?

    by Zacks Equity Research

    Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes

    by Zacks Equity Research

    Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

    Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track

    by Zacks Equity Research

    An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.

    Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Debanjana Dey headshot

    MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

    by Debanjana Dey

    MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

    Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment

    by Zacks Equity Research

    Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.

    Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic

    by Zacks Equity Research

    Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.

    Medtronic (MDT) to Expand Neuroscience Line With XENT Buyout

    by Zacks Equity Research

    Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.

    Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top

    by Zacks Equity Research

    Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

    Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?

    by Zacks Equity Research

    Intersect ENT (XENT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

    5 Probable MedTech Winners Post-COVID on Discounted PEG

    by Zacks Equity Research

    Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.

    Why Is Intersect ENT (XENT) Down 10.8% Since Last Earnings Report?

    by Zacks Equity Research

    Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Intersect ENT (XENT) Receives CE Mark for PROPEL Contour

    by Zacks Equity Research

    The CE Mark approval is backed by positive results from Intersect ENT's (XENT) PROGRESS clinical study of the PROPEL Contour.

    Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top

    by Zacks Equity Research

    Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

    Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Intersect ENT (XENT) delivered earnings and revenue surprises of -21.43% and 4.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?